Should I buy or sell 2seventy bio stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 2seventy bio in the last twelve months. There are currently 5 hold ratings, 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TSVT shares. View TSVT analyst ratings or view top-rated stocks .

What is 2seventy bio's stock price target for 2024?

10 brokers have issued twelve-month price targets for 2seventy bio's shares. Their TSVT share price targets range from $5.00 to $26.00. On average, they predict the company's share price to reach $12.86 in the next year. This suggests a possible upside of 183.2% from the stock's current price. View analysts price targets for TSVT or view top-rated stocks among Wall Street analysts .

How have TSVT shares performed in 2024?

2seventy bio's stock was trading at $4.27 at the beginning of 2024. Since then, TSVT shares have increased by 6.3% and is now trading at $4.54. View the best growth stocks for 2024 here .

When is 2seventy bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our TSVT earnings forecast .

How were 2seventy bio's earnings last quarter?

2seventy bio, Inc. (NASDAQ:TSVT) released its quarterly earnings results on Tuesday, March, 5th. The company reported ($1.11) earnings per share for the quarter, beating analysts' consensus estimates of ($1.22) by $0.11. The firm earned $10.68 million during the quarter, compared to analyst estimates of $13.91 million. 2seventy bio had a negative net margin of 313.51% and a negative trailing twelve-month return on equity of 67.59%. During the same quarter in the prior year, the business posted ($0.60) earnings per share.

What ETFs hold 2seventy bio's stock?

ETFs with the largest weight of 2seventy bio (NASDAQ:TSVT) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA) , Range Cancer Therapeutics ETF (CNCR) , Loncar China Biopharma ETF (CHNA) and Horizon Kinetics Medical ETF (MEDX) . Global X Genomics & Biotechnology ETF (GNOM) .

Who are 2seventy bio's major shareholders?

2seventy bio's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (7.26%), Healthcare of Ontario Pension Plan Trust Fund (3.38%), Jacobs Levy Equity Management Inc. (0.74%), Susquehanna Fundamental Investments LLC (0.27%), Wedmont Private Capital (0.17%) and Price T Rowe Associates Inc. MD (0.06%). Insiders that own company stock include Casdin Capital, Llc, Jessica Snow, Kynam Capital Management, Lp, Nick Leschly , Nicola Heffron , Philip D Gregory and William D Baird III . View institutional ownership trends .

How do I buy shares of 2seventy bio?

Shares of TSVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:TSVT

2seventy bio (TSVT) Stock Price, News & Analysis

→ **Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! (From Huge Alerts) (Ad)

Free TSVT Stock Alerts

$4.37

-0.43 (-8.96%)

(As of 03:00 PM ET)

Compare

Today's Range: $4.36
▼
$4.82
50-Day Range: $3.96
▼
$5.79
52-Week Range: $1.53
▼
$12.69

Volume: 240,685 shs
Average Volume: 1.23 million shs
Market Capitalization: $224.62 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.86

2seventy bio MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.60 Rating Score
Upside/Downside: 183.2% Upside
$12.86 Price Target
Short Interest: Bearish
14.59% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.32
Based on 3 Articles This Week
Insider Trading: Acquiring Shares
$3.14 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.93) to $0.19 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.33 out of 5 stars

Medical Sector

520th out of 918 stocks

Pharmaceutical Preparations Industry

245th out of 429 stocks

3.3

Analyst's Opinion

Consensus Rating
2seventy bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, 5 hold ratings, and no sell ratings.
Amount of Analyst Coverage
2seventy bio has only been the subject of 4 research reports in the past 90 days.
Read more about 2seventy bio's stock forecast and price target.

1.0

Short Interest

Percentage of Shares Shorted
14.59% of the float of 2seventy bio has been sold short.
Short Interest Ratio / Days to Cover
2seventy bio has a short interest ratio ("days to cover") of 6.3.
Change versus previous month
Short interest in 2seventy bio has recently increased by 7.41%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
2seventy bio does not currently pay a dividend.
Dividend Growth
2seventy bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TSVT.

1.8

News and Social Media Coverage

News Sentiment
2seventy bio has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for 2seventy bio this week, compared to 2 articles on an average week.
Search Interest
Only 3 people have searched for TSVT on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added 2seventy bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, 2seventy bio insiders have bought 4,247,332.43% more of their company's stock than they have sold. Specifically, they have bought $3,143,100.00 in company stock and sold $74.00 in company stock.
Percentage Held by Insiders
Only 2.60% of the stock of 2seventy bio is held by insiders.
Percentage Held by Institutions
93.90% of the stock of 2seventy bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Read more about 2seventy bio's insider trading history.

1.3

Earnings and Valuation

Earnings Growth
Earnings for 2seventy bio are expected to grow in the coming year, from ($0.93) to $0.19 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of 2seventy bio is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of 2seventy bio is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
2seventy bio has a P/B Ratio of 0.90. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.
Read more about 2seventy bio's valuation and earnings.

See Top Rated MarketRank™ Stocks Here

Ad Huge Alerts

**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1!

Learn more about why Zack’s has increased its price target on this company to a whopping $23.25!

Click for Zack's full report

About 2seventy bio Stock (NASDAQ:TSVT)

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

TSVT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TSVT Stock News Headlines

May 13, 2024 | americanbankingnews.com

Q2 2024 Earnings Forecast for 2seventy bio, Inc. Issued By Wedbush (NASDAQ:TSVT)

May 12, 2024 | americanbankingnews.com

Canaccord Genuity Group Cuts 2seventy bio (NASDAQ:TSVT) Price Target to $11.00

May 10, 2024 | markets.businessinsider.com

Buy Rating Affirmed for 2seventy bio on Strong Growth Prospects and Financial Stability

May 9, 2024 | msn.com

2seventy bio, Inc. (NASDAQ:TSVT) Q1 2024 Earnings Call Transcript

May 9, 2024 | finance.yahoo.com

2seventy bio Inc (TSVT) Q1 2024 Earnings: Misses Revenue Estimates Amid Strategic Realignments

May 9, 2024 | uk.finance.yahoo.com

2seventy bio Inc (TSVT) Q1 2024 Earnings Call Transcript Highlights: Strategic Shifts and ...

May 8, 2024 | markets.businessinsider.com

Here's what Wall Street expects from 2seventy bio's earnings

May 8, 2024 | investorplace.com

TSVT Stock Earnings: 2seventy bio Meets EPS, Misses Revenue for Q1 2024

May 8, 2024 | businesswire.com

2seventy bio Reports First Quarter Financial Results and Recent Operational Progress

May 3, 2024 | finance.yahoo.com

2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024

May 3, 2024 | businesswire.com

2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024

April 17, 2024 | msn.com

2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why

April 13, 2024 | morningstar.com

2seventy bio Inc Ordinary Shares

April 10, 2024 | investing.com

Citi raises 2Seventy Bio stock target on FDA approval

April 8, 2024 | markets.businessinsider.com

Positive Outlook for 2seventy bio’s ABECMA: Buy Rating Affirmed Amidst Expansion and Competitive Dynamics

April 7, 2024 | markets.businessinsider.com

Buy Rating and High Risk for 2seventy bio: FDA Approval and Market Expansion Fuel Optimistic Outlook

April 5, 2024 | msn.com

Bristol Myers Wins FDA Nod for Abecma

April 5, 2024 | msn.com

FDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary Cancer

April 5, 2024 | seekingalpha.com

Bristol Myers, 2seventy bio's Abecma approved for earlier line multiple myeloma

April 5, 2024 | finance.yahoo.com

U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy

March 20, 2024 | msn.com

2seventy bio appoints Eli Casdin and Charles Newton to its board of directors

March 20, 2024 | businesswire.com

2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors

March 20, 2024 | morningstar.com

Thinking about buying stock in 2Seventy Bio, Verb Technology, Exscientia, MicroCloud Hologram, or Akebia Therapeutics?

March 17, 2024 | marketwatch.com

Bristol Myers, 2seventy Bio's Cancer Treatment Wins FDA Committee Approval

March 16, 2024 | msn.com

Bristol Myers wins FDA AdCom backing for Abecma label expansion

See More Headlines

Company Calendar

Last Earnings: 3/05/2024
Today: 5/20/2024
Next Earnings (Estimated): 8/12/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:TSVT
CUSIP: N/A
CIK: 1860782
Web: www.2seventybio.com
Phone: 339-499-9300
Fax: N/A
Employees: 274
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $12.86
High Stock Price Target: $26.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +167.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.60
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.35)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-217,570,000.00
Net Margins: -313.51%
Pretax Margin: -313.51%
Return on Equity: -67.59%
Return on Assets: -31.71%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.52
Quick Ratio: 3.52

Sales & Book Value

Annual Sales: $100.39 million
Price / Sales: 2.46
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.04 per share
Price / Book: 0.95

Miscellaneous

Outstanding Shares: 51,400,000
Free Float: 50,068,000
Market Cap: $246.72 million
Optionable: Optionable
Beta: 1.87

Key Executives

Mr. Nick Leschly (Age 51)
President & Chairman of the Board
Comp: $1.81M
Mr. William D. Baird III (Age 52)
M.B.A., CEO & Director
Comp: $810.83k
Vicki Eatwell
Chief Financial Officer
Jessica Snow
Senior VP of Quality and Head of Operations
Michael Certo
VP & Head of Genome Editing
Anna Truppel-Hartmann
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TSVT Stock Analysis - Frequently Asked Questions

Should I buy or sell 2seventy bio stock right now?: 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 2seventy bio in the last twelve months. There are currently 5 hold ratings, 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TSVT shares.
View TSVT analyst ratings or view top-rated stocks.
What is 2seventy bio's stock price target for 2024?: 10 brokers have issued twelve-month price targets for 2seventy bio's shares. Their TSVT share price targets range from $5.00 to $26.00. On average, they predict the company's share price to reach $12.86 in the next year. This suggests a possible upside of 183.2% from the stock's current price.
View analysts price targets for TSVT or view top-rated stocks among Wall Street analysts.
How have TSVT shares performed in 2024?: 2seventy bio's stock was trading at $4.27 at the beginning of 2024. Since then, TSVT shares have increased by 6.3% and is now trading at $4.54.
View the best growth stocks for 2024 here.
When is 2seventy bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024.
View our TSVT earnings forecast.

How were 2seventy bio's earnings last quarter?: 2seventy bio, Inc. (NASDAQ:TSVT) released its quarterly earnings results on Tuesday, March, 5th. The company reported ($1.11) earnings per share for the quarter, beating analysts' consensus estimates of ($1.22) by $0.11. The firm earned $10.68 million during the quarter, compared to analyst estimates of $13.91 million. 2seventy bio had a negative net margin of 313.51% and a negative trailing twelve-month return on equity of 67.59%. During the same quarter in the prior year, the business posted ($0.60) earnings per share.
What ETFs hold 2seventy bio's stock?: ETFs with the largest weight of 2seventy bio (NASDAQ:TSVT) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), Range Cancer Therapeutics ETF (CNCR), Loncar China Biopharma ETF (CHNA) and Horizon Kinetics Medical ETF (MEDX).Global X Genomics & Biotechnology ETF (GNOM).
Who are 2seventy bio's major shareholders?: 2seventy bio's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (7.26%), Healthcare of Ontario Pension Plan Trust Fund (3.38%), Jacobs Levy Equity Management Inc. (0.74%), Susquehanna Fundamental Investments LLC (0.27%), Wedmont Private Capital (0.17%) and Price T Rowe Associates Inc. MD (0.06%). Insiders that own company stock include Casdin Capital, Llc, Jessica Snow, Kynam Capital Management, Lp, Nick Leschly, Nicola Heffron, Philip D Gregory and William D Baird III.
View institutional ownership trends.
How do I buy shares of 2seventy bio?: Shares of TSVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TSVT) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings

2seventy bio (TSVT) Stock Price, News & Analysis

2seventy bio MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Consensus Rating

Amount of Analyst Coverage

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Dividend Yield

Dividend Growth

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows